{
  "docId": "019de070-1b1e-715b-9181-3c5ed2b300ba",
  "docSlug": "b1852bb8f228b7adee18c4b9e730fd78",
  "documentTitle": "Calliditas Therapeutics | IPO Presentation Deck | 38 slides",
  "authorId": "calliditas-therapeutics",
  "authorName": "Calliditas Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2020-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 7,
  "pageCount": 38,
  "prevPage": 6,
  "nextPage": 8,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "balanced",
  "nDataPoints": 1,
  "notes": "The slide uses a numbered list format to present key value propositions.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-1b1e-715b-9181-3c5ed2b300ba/7",
  "deckHref": "/decks/019de070-1b1e-715b-9181-3c5ed2b300ba",
  "deckJsonHref": "/decks/019de070-1b1e-715b-9181-3c5ed2b300ba.json",
  "deckAnchorHref": "/decks/019de070-1b1e-715b-9181-3c5ed2b300ba#slide-7",
  "components": [
    {
      "bbox": {
        "h": 0.75,
        "w": 0.2,
        "x": 0.75,
        "y": 0.15
      },
      "kind": "image",
      "text": "Beaker with test tubes",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5157dac6-b620-4b01-9c3b-86b0ef3e5522",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.7,
        "w": 0.65,
        "x": 0.04,
        "y": 0.18
      },
      "kind": "list",
      "text": "1. Nefecon is a proprietary, novel treatment for IgAN intended to be disease modifying\n2. Nefecon targets the presumed origin of the disease – the area of the ileum where the highest concentration of Peyer's patches are located\n3. Nefecon is the most advanced product candidate for IgAN. The only successful randomized, double-blind, placebo-controlled Phase 2b clinical trial carried out in IgAN to date\n4. Ongoing pivotal Phase 3 clinical trial (NefIgArd) using the same primary endpoint as previous successful Phase 2b trial\n5. Regulatory pathway based on FDA and EMA acceptance of accelerated / conditional approval based on proteinuria as surrogate marker for IgAN\n6. Significant unmet medical need in IgAN with no currently approved treatments; total market opportunity of US$9-10bn in the U.S alone.\n7. Additional potential for pipeline development and in-licensing of product candidates targeting orphan diseases",
      "attrs": null,
      "subkind": "numbered",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1522f8b5-daab-4d0f-8246-527e0672beb4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.3,
        "x": 0.04,
        "y": 0.04
      },
      "kind": "title",
      "text": "Investment highlights",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "795b559e-5943-4c79-b6ed-c98ff890ad86",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Executive summary",
      "slug": "executive-summary",
      "agent": null,
      "layer": "slide",
      "matchId": "0867f584-6a6d-4003-af31-8dd25774541c",
      "evidence": "The slide contains a list/numbered of investment highlights, which is a common format for an executive summary.",
      "confidence": 0.9
    }
  ],
  "frameworks": [
    {
      "name": "list-presentation",
      "slug": null,
      "matchId": "0ad2f9ca-f58a-47ef-8c52-e19965c260e7",
      "evidence": "Numbered list of key value propositions",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}